Immunomodulatory effect of blood components transfusions;Immunomodulacyjny wpływ przetoczeń preparatów krwiopochodnych

Polski Merkuriusz Lekarski

Volumn 13, Issue 77, 2002, Pages 413-416

  Kłos, Mirosław ^a   Korsak, Jolanta ^a  

^a Centralny Bank Krwi   (Poland)

Author keywords

Blood components transfusions; Immunomodulation, clinical consequences

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ANIMAL CELL; BLOOD COMPONENT THERAPY; CELL ACTIVITY; CELL INTERACTION; CELLULAR IMMUNITY; CYTOTOXICITY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFORMATION; NONHUMAN; REVIEW; TH1 CELL; TH2 CELL;

BLOOD COMPONENT TRANSFUSION; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE SYSTEM; T-LYMPHOCYTES;

EID: 18844479389     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Anderson K.C., Weinstein H.J., Transfusion associated graft-versus-host disease. N. Engl. J. Med., 1990, 323, 315-321.
2. Benson K. i wsp.: Fatal graft versus-host disease associated with transfusions of HLA-matched. HLA-homozygous platelets from unrelated donors. Transfusion. 1994, 34, 432-437.
3. Blajchman M.A. i wsp.: Allogeneic blood transfusion-induced euhancement of tumor growth, Two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood, 1993, 81, 1880-1882.
4. Bordin J.O., Blajchman M.A., Transfusion associated immunosuppression. In, Principles of Transfusion Medicine (eds Rossi E.C., Simon TL., Moss G.S., Gould S.A.,). Williams and Wilkins. Baltimore. 1995, 803-812.
5. Bordin J.O., Hedddlle N.M., Blajchman M.A.: The biologic effects of leukocytes present in transfused cellular blood products. Blood, 1994, 84, 1703-1721,
6. Busch M.P. i wsp.: The viral activation transfusion study (VATS), rationale, objectives and design overview. Transfusion, 1996, 36, 854-859.
7. Claas F.H.J. i wsp.: Alloimmunization against MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp. Hematol., 1981, 9, 84-89.
8. Clark D.A., Gunby J., Daya S.: The use of allogenic leukocytes or IV IgM for the treatment of patients with recurrent spontaneous abortions. Transfus. Med. Rev., 1997, 11, 85-94.
9. De Gowin E.L., Hardin R.C., Alsever J.B.: Blood Transfusion. Saunders. Philadelphia, London. 1949.
10. Dzik W.H., Leukoreduced blood components. Laboratory and clinical aspects. In: Principles of Transfusion Medicine (eds Rossi E.C., Simon T.L., Moss G.S., Gould S.A.). Baltimore, MD. Williams and Wilkins. 1996, 353-373.
11. Dzik S. i wsp.: Current research on the immunomodulation effect of allogeneic blood transfusion. Vox Sang. 1996, 70, 1987-1994.
12. Eernisse J.G., Brand A.: Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp. Haematol., 1981, 9, 77-83.
13. Fast L.D, Recipient DC8+ cells are responsible for the rapid elimination of allogeneic donor limphoid cells. J. Immunol., 1996, 157, 4805-4810.
14. Frietsch T. I wsp.: Immune response to autologous transfusion in healthy volunters. WB versus packed RBCs and FFP. Transfusion, 2001, 41, 470-476.
15. Ghio M., Contini P., Mazzei C.: Soluble HLA class I, HLA class II, and Fas ligand in blood components, a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood, 1999, 93, 1770-1777.
16. Heiss M.M. i wsp.: Benefical effect of autologus blood transfusion on infections complications after colorectal cancer surgery. Lancet, 1993, 342, 1328-33.
17. Herzig R. H. i wsp.: Correction of poor platelet transfusion responses with leukocyte-poor HLA-matched platelet concentrates. Blood, 1975, 46, 743-750.
18. Jensen L.S. i wsp.: Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br. J. Surg., 1992, 79, 513-516.
19. Jensen L.S. i wsp.: Randomised comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and comlications after colorectal surgery. Lancet 1996, 348, 841-845.
20. Keynes G., The History of Blood Transfusion. (eds Keynes G., Wright J., Marhal S.). Bristol, London. 1949.
21. Muzcheff M.S. i wsp.: Blood transfusion and immunomodulation. A possible mechanism. Vox Sang. 1993, 65, 18-24.
22. Opelz G. i wsp.: Effect of blood transfusions on subsequent kidney transplants. Transplant. Proc., 1973, 5, 1, 252-259.
23. Opelz G. i wsp.: Prospective Evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation, 1997, 63, 964-967.
24. Pawelski S.: Rys historyczny leczenia krwia̧ i jej pochodnymi. W: Współczesna Transfuzjologia (red. Rudowski W., Pawelski S.). PZWL. Warszawa. 1985, 15-20.
25. Puppo F. i wsp.: Fas, Fas ligand and transfusion immunomodulation. Transfusion, 2001, 41, 416-418.
26. Puppo F. i wsp.: Serum HLA class I antigens, markers and modulators of an immune response. Immunol. Today, 1995, 16, 124-127.
27. Roelen D.L. i wsp.: Immunomodulation by blood transfusions. Vox Sang 2000, 78 suppl. 2, 273-275.
28. Sharma A.D. i wsp.: Leukocyte - Reduced blood transfusions, perioperative indications, adverse effects and cost analysis. Anesth. Analg., 2000, 90, 1315-1323.
29. Sloand E. i wsp.: Transfusion of blood components to persons infectet with human immunodeficiency virus type 1, Relationship to opportunistic infection. Transfusion, 1994, 34, 48-53.
30. Vamvakas E.C.: Transfusion-associated cancer recurrence and postoperative infection, Metaanalysis of randomized controlled clinical trials. Transfusion, 1996, 36, 176-186.
31. Vamvakas E.C., Carven J.H., Hibberd P.L.: Blood transfusion and infection after colorectal cancer surgery. Transfusion 1996, 36, 1000-1008.
32. Van der Mast B.J. i wsp.: Modulation of the T cell compartment by blood transfusion. Transplantation, 1997, 63, 1145-1154.